1. GLP-1 agonists are preferred in management of T2DM, weight reduction; they are free of hypoglycemia (used as second-line therapy as add-on + an insulin sensitizer such as metformin; as third-line therapy as add-on therapy to pre-existing dual combination therapy with metformin, SUs, TZD, alpha-glucosidase inhibitor).
2. Augmentation of the incretin axis by using GLP-1 agonists is a novel therapeutic concept, which is not only antihyperglycemic, but has considerable pleiotropic effects. Virtually every organ system in the body is benefited.
3. GLP-1 agonists provide CV stability (anti-ischemic, antihypertensive, inotropic, antiatherosclerotic), weight loss, neuronal protection; they also help improve liver and skeletal health and insulin resistance.
4. GLP-1 has been shown to have a positive influence on macrophage-mediated inflammatory response and tissue remodeling, which may have benefits in suppression of vascular inflammation and improvement in wound healing.

“Incretin therapy clearly represents the future of antidiabetes therapy give its impressive pleiotropic actions”.